RxDoctor Payments Data

Marissa de la Paz, MD

Family Medicine · Cabot, ARNPI 1871090456

Payments from drug & device makers

$5,783in general payments, 2019–2025

Across 320 payments — averaging $18.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$806
  • AbbVie$744
  • Lilly USA, LLC$614
  • Pfizer$424
  • GSK$283
  • plus $2K from 29 others

What the payments were for

  • Food & beverage$5,783100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,783 in reported general payments places this provider in the 85th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$80,333
Medicare patients
201
Services billed
1,587

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide97$108,655
MounjaroTirzepatide65$76,993
FarxigaDapagliflozin Propanediol55$62,744
TrulicityDulaglutide21$28,877
JardianceEmpagliflozin23$27,415
TradjentaLinagliptin26$26,056
EliquisApixaban14$21,178
MyrbetriqMirabegron16$12,364
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$12,209
NexlizetBempedoic Acid/Ezetimibe11$12,101
LinzessLinaclotide12$11,530
Soliqua 100-33Insulin Glargine/Lixisenatide12$9,336
TrintellixVortioxetine Hydrobromide13$6,135
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog12$4,044
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog12$4,019

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$806$108,65597 claims
Lilly USA, LLCMounjaro, Trulicity$614$105,87086 claims
AstraZenecaFarxiga$1,012$62,74455 claims
Boehringer IngelheimJardiance, Tradjenta$46$53,47149 claims
PfizerEliquis$424$21,17814 claims
AbbVieLinzess, Synthroid$744$14,12449 claims
Astellas Pharma US IncMyrbetriq$40$12,36416 claims
GSKTrelegy Ellipta$283$12,20911 claims
Esperion Therapeutics, Inc.Nexlizet$140$12,10111 claims
Sanofi-aventis U.S. LLCSoliqua 100-33$13$9,33612 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$171$6,13513 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Cabot

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →